RU2019120990A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019120990A3 RU2019120990A3 RU2019120990A RU2019120990A RU2019120990A3 RU 2019120990 A3 RU2019120990 A3 RU 2019120990A3 RU 2019120990 A RU2019120990 A RU 2019120990A RU 2019120990 A RU2019120990 A RU 2019120990A RU 2019120990 A3 RU2019120990 A3 RU 2019120990A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435253P | 2016-12-16 | 2016-12-16 | |
| US62/435,253 | 2016-12-16 | ||
| PCT/US2017/066317 WO2018112149A1 (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019120990A3 true RU2019120990A3 (ru) | 2021-01-18 |
| RU2019120990A RU2019120990A (ru) | 2021-01-18 |
| RU2753056C2 RU2753056C2 (ru) | 2021-08-11 |
Family
ID=62557188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120990A RU2753056C2 (ru) | 2016-12-16 | 2017-12-14 | Бициклические гетероарильные производные в качестве стимуляторов cftr |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10131670B2 (ru) |
| EP (1) | EP3554506B1 (ru) |
| JP (1) | JP7150721B2 (ru) |
| CN (1) | CN110300589B (ru) |
| AU (2) | AU2017378324B2 (ru) |
| CA (1) | CA3046968A1 (ru) |
| MX (1) | MX391651B (ru) |
| RU (1) | RU2753056C2 (ru) |
| SG (2) | SG10201911221RA (ru) |
| WO (1) | WO2018112149A1 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| CA3004798C (en) | 2015-11-25 | 2023-10-31 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
| PL3380480T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Pirazolowe inhibitory acc i ich zastosowania |
| PL3379933T3 (pl) | 2015-11-25 | 2023-07-24 | Gilead Apollo, Llc | KOMPOZYCJE GRZYBOBÓJCZE ZAWIERAJĄCE POCHODNE 2,4-DIOKSO-1,4-DIHYDROTIENO[2,3-d]PIRYMIDYNY |
| EP3380479B1 (en) | 2015-11-25 | 2022-12-07 | Gilead Apollo, LLC | Triazole acc inhibitors and uses thereof |
| TN2019000079A1 (en) | 2016-09-30 | 2020-07-15 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI774712B (zh) | 2016-12-09 | 2022-08-21 | 美商維泰克斯製藥公司 | 囊性纖維化跨膜傳導調控劑之調節劑、醫藥組合物、治療方法及製備該調節劑之方法 |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| KR102606188B1 (ko) | 2017-08-02 | 2023-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 피롤리딘 화합물을 제조하기 위한 공정 |
| IL273831B2 (en) | 2017-10-19 | 2024-10-01 | Vertex Pharma | Crystalline forms and compositions of cftr modulators |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| FI3752510T3 (fi) | 2018-02-15 | 2023-03-14 | Vertex Pharma | Makrosyklit kystisen fibroosin transmembraanisen konduktanssinsäätäjän modulaattoreina, niiden farmaseuttisia koostumuksia, niiden käyttö kystisen fibroosin hoidossa ja menetelmä niiden valmistamiseksi |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) * | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CN113891744A (zh) * | 2019-06-10 | 2022-01-04 | 诺华股份有限公司 | 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物 |
| KR20220035421A (ko) | 2019-07-15 | 2022-03-22 | 노파르티스 아게 | (s)-3-아미노-6-메톡시-n-(3,3,3-트리플루오로-2-히드록시-2-메틸프로필)-5-(트리플루오로메틸)피콜린아미드의 제형 |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| CN114599657B (zh) | 2019-08-14 | 2024-10-11 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
| EP4199914A4 (en) | 2020-08-20 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATMENT OF RESPIRATORY DISEASES CHARACTERIZED BY HYPERSECRETION OF MUCUS |
| US12186306B2 (en) | 2020-12-10 | 2025-01-07 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN112876524B (zh) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | 一种瑞德西韦中间体的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| MX2008007103A (es) | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
| JP5512975B2 (ja) * | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
| EA200870409A1 (ru) * | 2006-04-04 | 2009-04-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы pi3 |
| JP2011503103A (ja) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
| PH12012501587A1 (en) | 2010-02-05 | 2020-10-19 | Adverio Pharma Gmbh | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| CA2915418C (en) * | 2013-07-02 | 2022-05-03 | Rhizen Pharmaceuticals Sa | Novel selective pi3k delta and/or gamma protein kinase inhibitors |
| US10301315B2 (en) | 2016-11-18 | 2019-05-28 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrrolopyrimidines as CFTR potentiators |
-
2017
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/ru active
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/zh active Active
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/ja active Active
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
- 2017-12-14 MX MX2019007135A patent/MX391651B/es unknown
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en unknown
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3046968A1 (en) | 2018-06-21 |
| MX391651B (es) | 2025-03-21 |
| US10131670B2 (en) | 2018-11-20 |
| JP2020502103A (ja) | 2020-01-23 |
| US10377762B2 (en) | 2019-08-13 |
| US20190016727A1 (en) | 2019-01-17 |
| AU2017378324A1 (en) | 2019-06-27 |
| EP3554506B1 (en) | 2021-04-28 |
| EP3554506A1 (en) | 2019-10-23 |
| JP7150721B2 (ja) | 2022-10-11 |
| AU2021277702B2 (en) | 2023-11-30 |
| US10208053B2 (en) | 2019-02-19 |
| EP3554506A4 (en) | 2020-06-10 |
| AU2021277702A1 (en) | 2021-12-23 |
| CN110300589B (zh) | 2023-03-10 |
| WO2018112149A1 (en) | 2018-06-21 |
| US20190016728A1 (en) | 2019-01-17 |
| SG10201911076QA (en) | 2020-01-30 |
| BR112019012335A2 (pt) | 2020-03-03 |
| AU2017378324B2 (en) | 2021-09-02 |
| SG10201911221RA (en) | 2020-02-27 |
| US20190330219A1 (en) | 2019-10-31 |
| RU2019120990A (ru) | 2021-01-18 |
| US10766904B2 (en) | 2020-09-08 |
| MX2019007135A (es) | 2019-11-18 |
| US20180170938A1 (en) | 2018-06-21 |
| RU2753056C2 (ru) | 2021-08-11 |
| CN110300589A (zh) | 2019-10-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |